Pliant Therapeutics (PLRX) Research & Development (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Research & Development of $13.6 million for Q1 2026, down 68.73% year-over-year from $43.4 million in Q1 2025, and down 12.84% quarter-over-quarter from $15.6 million in Q4 2025.
Pliant Therapeutics (PLRX) Research & Development (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Research & Development for 8 consecutive years, with $13.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 68.73% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $79.3 million (down 54.84% YoY), while the FY2025 annual figure was $109.2 million, down 35.53% from the prior year.
- Research & Development fell to $13.6 million in Q1 2026 per PLRX's latest filing, from $15.6 million in the prior quarter.
- Across five years, Research & Development topped out at $47.8 million in Q3 2024 and bottomed at $13.6 million in Q1 2026.
- Historically, Research & Development has averaged $30.4 million across 5 years, with a median of $32.2 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development surged 47.67% — and 2026, when it slumped 68.73%.
- Pliant Therapeutics' Research & Development stood at $25.1 million in 2022, then soared by 32.13% to $33.2 million in 2023, then increased by 16.91% to $38.8 million in 2024, then plunged by 59.83% to $15.6 million in 2025, then declined by 12.84% to $13.6 million in 2026.
- Business Quant data shows PLRX's Research & Development at $13.6 million in Q1 2026, $15.6 million in Q4 2025, and $17.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 16.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.73 Mn |
| Mar 31, 2026 | 13.58 Mn |
| Dec 31, 2025 | 15.59 Mn |
| Sep 30, 2025 | 17.94 Mn |
| Jun 30, 2025 | 32.20 Mn |
| Mar 31, 2025 | 43.44 Mn |
| Dec 31, 2024 | 38.79 Mn |
| Sep 30, 2024 | 47.75 Mn |
| Jun 30, 2024 | 45.62 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Dec 31, 2023 | 33.18 Mn |
| Sep 30, 2023 | 32.34 Mn |
| Jun 30, 2023 | 33.00 Mn |
| Mar 31, 2023 | 29.27 Mn |
| Dec 31, 2022 | 25.11 Mn |
| Sep 30, 2022 | 24.61 Mn |
| Jun 30, 2022 | 26.34 Mn |
| Mar 31, 2022 | 20.88 Mn |
| Dec 31, 2021 | 18.75 Mn |
| Sep 30, 2021 | 21.05 Mn |